

To,
The General Manager,
Department of Corporate Services,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400001,
Maharashtra, India

Scrip Code: 541735

ISIN: INE299W01022

Subject: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Execution of Business Collaboration Agreements with Qness Pharmaceuticals

Dear Sir/Madam,

Pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that **Vivanta Industries Limited ("the Company")** has entered into certain business collaboration agreements with **Qness Pharmaceuticals**, a proprietorship concern, in connection with the manufacture, supply, branding and marketing of pharmaceutical and allied products.

The brief details of the agreements are as under:

| Sr. No. | Particulars | Details |
|---------|---|---|
| 1 | Name of the entity with whom agreement is signed | Qness Pharmaceuticals (Proprietorship Concern) |
| 2 | Area of agreement | Collaboration for manufacture, procurement, supply, branding, marketing and distribution of pharmaceutical and allied products. |
| 3 | Domestic/International | Domestic |
| 4 | Share exchange ratio | Not Applicable, as the arrangement does not involve any joint venture, equity participation or share exchange. |
| 5 | Scope of business operation of agreement | The parties shall collaborate for manufacture and/or procurement of pharmaceutical products and undertake branding, supply and distribution activities in accordance with the terms of the respective agreements and mutually agreed commercial arrangements. |
| 6 | Details of consideration /received of paid in agreement | No upfront consideration has been paid or received. Commercial consideration shall be determined on the basis of individual purchase orders and mutually agreed commercial terms from time to time. |

| | | |
|----|---|---|
| 7 | Significant terms and conditions of agreement in brief | The agreements provide a framework for manufacture, procurement, supply, branding and distribution of pharmaceutical products. Ownership of intellectual property shall remain with the respective owner. Product-wise pricing and operational terms shall be governed through mutually agreed purchase orders. The agreements do not result in any transfer of management or control of the Company. |
| 8 | Whether the arrangement falls within related party transactions and whether the promoter/promoter group/group companies have any interest | No. The counterparty is not a related party of the Company. The Promoters, Promoter Group and Group Companies of the Company have no interest in the said arrangements. The transactions are proposed to be undertaken on an arm's length basis. |
| 9 | Size of the entity | Qness Pharmaceuticals is a proprietorship concern engaged in the business of pharmaceutical products. |
| 10 | Rationale and benefit expected | The agreements are expected to strengthen the Company's business collaboration in the pharmaceutical sector, expand its product portfolio, enhance market reach and create opportunities for business growth through contract manufacturing and supply arrangements. |

Further, in the event the aforesaid arrangements are terminated or called off for any reason, the Company shall make appropriate disclosure to the Stock Exchange along with the reasons thereof, in accordance with the applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

Thanking you.

Yours faithfully,

For Vivanta Industries Limited

Devang Shah
Company Secretary & Compliance Officer